IMRN - Dhuwit awis perusahaan Immuron Inc

IMRN (Immuron Limited) - tandha merek perusahaan

Immuron Limited is developing innovative gastrointestinal treatments in collaboration with the U.S. Department of Defense. The niche status of antibodies used to combat diarrhea allows for flexible pricing power. However, marketing expenses and FDA expectations are creating financial pressure. The cash balance history demonstrates current liquidity, where the value is maintained at 0.01, helping to assess the company's resilience.

Dana dhuwit perusahaan: Immuron Limited (IMRN) kanggo 04.07.2022 - 21.11.2026

Rincian metrik lan analitis perusahaan Immuron Limited (IMRN)

- nilai saham lan prakiraan konsensus rega:
Analisis dhasar perusahaan:Immuron IMRN
Produk mawa merek Immuron Inc

This indicator measures the volume of liquid assets of Immuron Limited (IMRN), allowing for a real-time assessment of the company's solvency and financial cushion. The current cash level stands at 0.01, which is critical for ensuring the commercial scaling of drugs through pharmacy chains and optimizing operating expenses during production expansion, confirming the resilience of the issuer's investment profile.